Project Grant W81XWH2110312

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $304,629 to support the preclinical development of LCTG-001, a human secretory IgA (sIgA) replacement therapy for patients with common variable immune deficiency (CVID). The funding will enable the awardee, Lactiga US Inc., to develop a non-clinical intranasal pharmacokinetic profile and formulation framework for...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) totaling $673,379 will support the development of a novel synthetic biology-based cellular immunotherapy for treating ulcerative colitis. The primary awardee, Rise Therapeutics LLC, is advancing their lead candidate R-3750, an engineered Lactococcus lactis strain that expresses the anti-inflammatory surface layer protein A...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,255,725 to the Icahn School of Medicine at Mount Sinai to advance the development and manufacture of defined live microbial therapeutics for the treatment of infectious and inflammatory diseases. The key objectives of this 4-year project are to: 1) Develop a solid-state fermentation...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $817,161 to investigate the use of mesenchymal stem cells (MSCs) derived from the human gut as a novel autologous cell therapy for treating perianal fistulas, a serious complication of Crohn's disease. The 3-year research project, led by Mercer University in Macon, Georgia, aims to characterize the potency and...

The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Siolta Therapeutics Inc. on August 14, 2023. The purpose of this grant is to develop STMC-106, a multistrain live biotherapeutic product (LBP), for the prevention and treatment of necrotizing enterocolitis (NEC) in preterm infants. The key objectives of this project are: 1) to identify combinations of therapeutic...

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $919,404 to Qrono, Inc. to develop QR401, a first-in-class oral nanomedicine targeting antigen-presenting cells (APCs) for the treatment of inflammatory bowel disease (IBD). The goal is to leverage the AMPK pathway to restore immune tolerance and alleviate intestinal...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Biotherapeutics, Inc. to accelerate the development of a novel, oral, first-in-class immunoregulatory therapeutic for the treatment of Clostridioides difficile infection (CDI). The key objectives are to: 1) Evaluate the comparative efficacy of the product candidate versus FDA-approved CDI therapeutics in...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $502,752 to Washington University in St. Louis to investigate the role of endoplasmic reticulum (ER) stress in controlling innate lymphoid cells in intestinal inflammation. The five-year research project, led by Dr. Siyan Cao, aims to elucidate the mechanistic role of the IRE1α-XBP1 pathway in regulating innate...

This Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research aimed at reprogramming intestinal immunity in preterm neonates to prevent and treat necrotizing enterocolitis (NEC), a severe and often fatal intestinal disease of prematurity. The $2,175,283 grant, awarded on August 15, 2024, will leverage a unique biorepository of samples from preterm infants with and...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $584,750 to Foli Bio Inc. to validate the functional utility of their EXFO-SEQ technology. EXFO-SEQ is an innovative platform that enables the precise and robust quantification of host gene expression directly from stool samples, providing a non-invasive means to longitudinally profile...